Analysts See $-1.14 EPS for DBV Technologies S.A. (DBVT)

March 16, 2018 - By Vivian Park

 Analysts See $ 1.14 EPS for DBV Technologies S.A. (DBVT)

Analysts expect DBV Technologies S.A. (NASDAQ:DBVT) to report $-1.14 EPS on March, 21. The stock decreased 3.60% or $0.81 during the last trading session, reaching $21.67. About 148,294 shares traded. DBV Technologies S.A. (NASDAQ:DBVT) has risen 16.91% since March 16, 2017 and is uptrending. It has outperformed by 0.21% the S&P500.

DBV Technologies S.A. (NASDAQ:DBVT) Ratings Coverage

Among 10 analysts covering DBV Technologies (NASDAQ:DBVT), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. DBV Technologies has $72 highest and $25.0 lowest target. $41.89’s average target is 93.31% above currents $21.67 stock price. DBV Technologies had 22 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was initiated by Morgan Stanley on Tuesday, September 15 with “Overweight”. Jefferies maintained the stock with “Buy” rating in Thursday, August 31 report. Barclays Capital initiated DBV Technologies S.A. (NASDAQ:DBVT) on Thursday, December 3 with “Overweight” rating. The firm has “Buy” rating given on Friday, October 23 by Bank of America. Jefferies initiated it with “Buy” rating and $47.0 target in Tuesday, October 13 report. The stock of DBV Technologies S.A. (NASDAQ:DBVT) has “Hold” rating given on Tuesday, October 31 by Societe Generale. H.C. Wainwright maintained DBV Technologies S.A. (NASDAQ:DBVT) on Thursday, July 6 with “Buy” rating. The rating was maintained by Jefferies with “Buy” on Thursday, June 1. The rating was maintained by Barclays Capital with “Overweight” on Monday, October 23. The firm has “Sell” rating by Societe Generale given on Tuesday, October 24.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. The company has market cap of $1.08 billion. The Company’s lead product candidate is Viaskin Peanut, an immunotherapy product, which is in Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. It currently has negative earnings. The firm is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.